Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials
Jeremy Braybrooke(University Hospitals Bristol NHS Foundation Trust), Philip Morris, Zhi‐Ming Shao(Shanghai Medical College of Fudan University), Toru Watanabe(Yamagata University), Lucy Davies(Nuffield Orthopaedic Centre), Ulrike Nitz(Women‘s Healthcare Group), Jo Gay, Lucy Gettins, Hui Lui, Fátima Cardoso(Breast Cancer Alliance), Nadia Harbeck(Breast Center), Kazutaka Narui, Maj‐Britt Jensen(Aarhus University Hospital), Rosie Bradley, Jon Godwin, Bent Ejlertsen, E. Mamounas, Stewart Anderson(Zimmer Biomet (Netherlands)), Tomohiko Aihara(Osaka International Cancer Institute), Larry Norton(Memorial Sloan Kettering Cancer Center), Thomas W. P. Friedl, Joanne L. Blum(Texas Oncology), John Crown(St. Vincent's University Hospital), Robert K. Hills(Cancer Research UK Clinical Trials Unit), Theresa McHugh, Zulian Lui, Greg Yothers(University of Pittsburgh), Dennis Slamon, Elizabeth MacKinnon, Ke‐Da Yu(Fudan University Shanghai Cancer Center), Clare Boddington, Mike Clarke(University College Dublin), Joyce O’Shaughnessy(Baylor University Medical Center), Nicholas J. Robert(Tufts Medical Center), Gurdeep Mannu, Christina Davies, Frances Duane(St. Luke's Hospital), Joseph A. Sparano(Tisch Cancer Institute), Martine Piccart(Université Libre de Bruxelles), Paul McGale, Richard Gray(Barnsley Hospital NHS Foundation Trust), Carolyn Taylor(University of Oxford), Xiaosong Chen(Shanghai Jiao Tong University), Hongchao Pan(Cancer Hospital of Shantou University Medical College), Richard Berry, Vaughan Evans, Richárd Pető(University of Oxford), Sam James, Wolfgang Janni(Universität Ulm), David Dodwell(University of Oxford)
Cited by 198
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Current and future burden of breast cancer: Global statistics for 2020 and 2040
|The Breast|2022|3.3k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k